MedPAC advocates for MIPS termination November 01, 2017By Bob GattyIf members of the Medicare Payment Advisory Commission have their way, the new Merit-based Incentive Payment System will be sent into oblivion, never to be heard of again.
In this issue
Senate takes aim at pharmacy benefit managers’ role in rising drug costs November 01, 2017By Brian HendersonA recently proposed bill “offers transparency measures that provide stakeholders further elucidation of how money moves through the pharmaceutical supply chain,” writes the AACU’s Brian Henderson.
Pair of genes may predict prostate cancer metastasis November 06, 2017By Andrew BowserOverexpression of a specific pair of genes might provide early warning of prostate cancer patients’ likelihood of progressing to metastatic disease.
Why you need to better counsel PCa patients on sexual function November 06, 2017By Lisette HiltonThere’s a troubling disconnect between low-risk prostate cancer patients’ desire to preserve sexual function and the treatment choices they and their doctors often make.
LUGPA advocacy targets self-referral laws, USPSTF reform November 11, 2017By Bob GattyIn his health policy briefing, Deepak A. Kapoor, MD, discusses LUGPA’s comments to CMS regarding MACRA and the 2018 Medicare physician fee schedule.
Urology-specific APMs to encompass PCa, BPH, OAB“The APMs being designed by LUGPA allow for participation by all urologists regardless of their practice setting or affiliation,” explains Alec Koo, MD.
How care process models can help your practice“Care process models… represent a way to decrease variation and waste, and thereby they lead to improved outcomes and significant cost reductions,” says Jay T. Bishoff, MD.
LUGPA puts resources behind key policy initiatives, future leaders November 11, 2017By Bob GattyThe association and its member groups are “leading the way” in developing urology-specific measures that can be used for MIPS quality reporting, says LUGPA President Neal D. Shore, MD.
Prevent burnout by restoring professional fulfillment“The answer is to remove the barriers and frustrations that are causing burnout so that physicians can focus on their role as care providers,” advises Paul DeChant, MD, MBA.
PCa active surveillance trends revealed in ‘real-world’ study November 12, 2017By Bob GattyNearly three-fourths of men with very low-risk prostate cancer underwent active surveillance as a primary therapy, according to a study presented at the LUGPA annual meeting in Chicago.
Sacral neuromodulation, botulinum show equal efficacy November 14, 2017By Andrew BowserIn patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial. How to reduce opioid use in post-op patients November 01, 2017By Stephen Y. Nakada MDIn this interview, urologist Francis J. McGovern, MD, discusses the scope of the problem of opioid abuse, outlines opioid-sparing strategies, and explains what the future holds in this area. IC/BPS: One-fourth of patients have Hunner lesions November 01, 2017By Wayne KuznarAbout one-fourth of patients with interstitial cystitis/bladder pain syndrome have Hunner lesions in the bladder visible on cystoscopy. Cisplatin nanoparticles appear efficacious for treating NMIBC November 15, 2017By Lisette HiltonThe use of intravesical cisplatin nanoparticles reduces cancer cell proliferation while limiting drug absorption beyond the bladder barrier, according to early findings.
Bladder Ca subtypes ID’d, may yield personalized therapies November 15, 2017By Andrew BowserResearchers from The Cancer Genome Atlas Research Network have outlined five distinct expression subtypes of muscle-invasive bladder cancer, each of which may be targetable by different treatments.
Immediate post-TURBT mitomycin instillation reduces recurrence risk November 01, 2017By Badar M. Mian MDMitomycin C instillation within 24 hours after transurethral resection of non-muscle invasive bladder cancer significantly reduces the risk of recurrence and delays the time to recurrence.
Repeat hydrodistention found safe in treating IC November 01, 2017By Wayne KuznarRepeated hydrodistention as therapy for interstitial cystitis has a low complication rate and does not decrease bladder capacity over time.
PSA screening: What do you tell primary care docs?
November 16, 2017We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area.
Shock waves may change future of ED therapy November 17, 2017By Lisette HiltonIt’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising. If disaster strikes, is your practice prepared? November 17, 2017By Lisette HiltonA month after Hurricane Harvey’s aftermath, Houston-based urologist Steven Canfield, MD, says his practice is still having to reschedule operating room times to help out with the hurricane-induced OR shortage. Are you taking steps to prevent data breaches? November 01, 2017By Robert A. Dowling MD"Urologists need to be ever more vigilant to protect the private information under their custodianship," writes Robert A. Dowling, MD. Survey: Urologists lack knowledge, training in transgender care
November 20, 2017While urologists are generally comfortable discussing patients’ sexual orientation, they report that both their knowledge of care of transgender patients and training in such care are lacking.
Cost variation among urologists: Can we trim the fat? November 20, 2017By Henry Rosevear MD"All the surgeons I know think that while they may not be the best in the world at what they do, they are clearly above average (think Lake Wobegon, but as adults). Hence, it can be a little disconcerting when data is produced that suggests that at least half of us have room for improvement," writes Henry Rosevear, MD. Foot stimulation may offer home-based OAB treatment November 01, 2017By Richard R. KerrNew research may pave the way for a form of nerve stimulation for refractory overactive bladder that is home based and less invasive than current neuromodulation approaches. Genomic testing linked to higher surveillance uptake November 01, 2017By Wayne KuznarIn men with clinically low-risk prostate cancer managed in community-based urology practices, utilization of active surveillance as initial management is higher among those who undergo genomic testing. Uro Pipeline: NDA submitted for non-metastatic castration-resistant PCa agent
November 27, 2017Other pipeline products discussed in this round-up include and advanced renal cell carcinoma agent, a bladder cancer detection agent, and a BPH treatment.
ABU: Life-long learning will be relevant, less burdensome"The ABU is committed to evolving a [life-long learning] program that diplomates find relevant and less burdensome. We will always welcome diplomates’ feedback regarding this evolving program," writes H. Ballentine Carter, MD. What one thing about MOC would you change if you could? November 01, 2017By Karen Nash“I’d like to see [the American Board of Urology] do something to make the process more applicable to our practice,” says one urologist.
How incidental radiology findings can lead to malpractice litigation"Incidental radiology findings are low-hanging fruit that organizations should develop processes for handling proactively," writes Brianne Goodwin, JD, RN. CCP score further risk stratifies surveillance candidates November 01, 2017By Wayne KuznarUse of a cell cycle progression genomics test (Prolaris) can further stratify risk in men who are candidates for active surveillance based on clinical criteria, and therefore may have a role in decision-making in men with early-stage prostate cancer, researchers say.
Cost considerations in the management of bladder cancer"We will review the evidence and identify potential areas of improvement that can help reduce costs associated with UCB management while improving outcomes," write Daniel J. Lee, MD, and Sam S. Chang, MD.